Positive News SentimentPositive NewsNASDAQ:DVAX Dynavax Technologies (DVAX) Stock Price, News & Analysis $11.36 -0.02 (-0.18%) (As of 11:07 AM ET) Add Compare Share Share Today's Range$11.27▼$11.3850-Day Range$10.05▼$12.0152-Week Range$9.74▼$15.15Volume256,368 shsAverage Volume2.11 million shsMarket Capitalization$1.49 billionP/E Ratio189.33Dividend YieldN/APrice Target$23.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Dynavax Technologies alerts: Email Address Dynavax Technologies MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside108.3% Upside$23.67 Price TargetShort InterestBearish13.67% of Shares Sold ShortDividend StrengthN/ASustainability-1.59Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$43,127 Sold Last QuarterProj. Earnings Growth108.33%From $0.12 to $0.25 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.39 out of 5 starsMedical Sector129th out of 924 stocksPharmaceutical Preparations Industry45th out of 426 stocks 3.4 Analyst's Opinion Consensus RatingDynavax Technologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageDynavax Technologies has only been the subject of 2 research reports in the past 90 days.Read more about Dynavax Technologies' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.67% of the outstanding shares of Dynavax Technologies have been sold short.Short Interest Ratio / Days to CoverDynavax Technologies has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Dynavax Technologies has recently increased by 3.95%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldDynavax Technologies does not currently pay a dividend.Dividend GrowthDynavax Technologies does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDynavax Technologies has received a 74.16% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Hepatitis B vaccines", "Clinical research services for infectious diseases", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Dynavax Technologies is -1.59. Previous Next 3.2 News and Social Media Coverage News SentimentDynavax Technologies has a news sentiment score of 1.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Dynavax Technologies this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for DVAX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows2 people have added Dynavax Technologies to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dynavax Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $43,127.00 in company stock.Percentage Held by InsidersOnly 2.98% of the stock of Dynavax Technologies is held by insiders.Percentage Held by Institutions96.96% of the stock of Dynavax Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Dynavax Technologies' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Dynavax Technologies are expected to grow by 108.33% in the coming year, from $0.12 to $0.25 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dynavax Technologies is 189.33, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 145.08.Price to Earnings Ratio vs. SectorThe P/E ratio of Dynavax Technologies is 189.33, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 138.68.Price to Book Value per Share RatioDynavax Technologies has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Dynavax Technologies' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchThe Strange Disappearance of MILLIONS of American JobsA former hedge fund manager who bought Apple at a split-adjusted 35 cents and Amazon at $2.40 (split adjusted) just went issued a major warning.You can watch our interview, here, free of charge. About Dynavax Technologies Stock (NASDAQ:DVAX)Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.Read More DVAX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DVAX Stock News HeadlinesAugust 12, 2024 | americanbankingnews.comDynavax Technologies (NASDAQ:DVAX) Price Target Cut to $15.00August 10, 2024 | finance.yahoo.comDynavax Technologies Corporation Just Recorded A 28% EPS Beat: Here's What Analysts Are Forecasting NextAugust 22, 2024 | Stansberry Research (Ad)Millionaire Investor Warns: “Brace for Apple Collapse”Apple stock has quadrupled over the past five years. But now even Warren Buffett is pulling the plug. The Oracle of Omaha just sold HALF his stake – worth more than $75 billion in the iconic tech company.August 7, 2024 | msn.comDynavax Technologies Corporation (NASDAQ:DVAX) Q2 2024 Earnings Call TranscriptAugust 7, 2024 | markets.businessinsider.comDynavax’s Market Dominance and Buoyant Growth Prospects Affirm Buy RatingAugust 7, 2024 | markets.businessinsider.comDynavax Stock Hold Rating Maintained Amidst Sales Uncertainty and Pipeline RisksAugust 7, 2024 | markets.businessinsider.comDynavax’s Strong Growth and Market Share Expansion Drive Buy RatingAugust 7, 2024 | msn.comDynavax Technologies (DVAX) Q2 2024 Earnings Call TranscriptAugust 22, 2024 | Stansberry Research (Ad)Millionaire Investor Warns: “Brace for Apple Collapse”Apple stock has quadrupled over the past five years. But now even Warren Buffett is pulling the plug. The Oracle of Omaha just sold HALF his stake – worth more than $75 billion in the iconic tech company.August 6, 2024 | investorplace.comDVAX Stock Earnings: Dynavax Technologies Beats EPS, Misses Revenue for Q2 2024August 6, 2024 | prnewswire.comDynavax Reports Second Quarter 2024 Financial Results and Provides Business UpdatesAugust 6, 2024 | markets.businessinsider.comDynavax Technologies is about to announce earnings — here's what Wall Street expectsJuly 23, 2024 | prnewswire.comDynavax to Report Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024June 27, 2024 | prnewswire.comDynavax Initiates Phase 1/2 Study of Novel Shingles Vaccine ProgramMay 28, 2024 | prnewswire.comDynavax to Present at Upcoming Investor ConferencesMay 14, 2024 | finanznachrichten.deDynavax Technologies: Dynavax Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B Regimen for Adults on Hemodialysis in the U.S.May 14, 2024 | markets.businessinsider.comHold Rating on Dynavax Amidst FDA Setback and Long-term Profitability FocusMay 14, 2024 | markets.businessinsider.comDynavax Receives FDA's CRL Regarding Four-Dose Heplisav-B Vaccine For Hemodialysis PatientsSee More Headlines Receive DVAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dynavax Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today8/22/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:DVAX CUSIP26815810 CIK1029142 Webwww.dynavax.com Phone(510) 848-5100Fax510-848-1327Employees408Year Founded1996Price Target and Rating Average Stock Price Target$23.67 High Stock Price Target$29.00 Low Stock Price Target$15.00 Potential Upside/Downside+108.0%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$0.06 Trailing P/E Ratio189.67 Forward P/E Ratio94.83 P/E GrowthN/ANet Income$-6,390,000.00 Net Margins3.91% Pretax Margin3.33% Return on Equity1.52% Return on Assets0.95% Debt Debt-to-Equity Ratio0.36 Current Ratio15.20 Quick Ratio14.10 Sales & Book Value Annual Sales$249.69 million Price / Sales5.97 Cash FlowN/A Price / Cash FlowN/A Book Value$4.81 per share Price / Book2.37Miscellaneous Outstanding Shares130,892,000Free Float126,991,000Market Cap$1.49 billion OptionableOptionable Beta1.28 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Ryan Spencer (Age 46)CEO, Interim CFO & Director Comp: $1.49MMr. David F. Novack (Age 62)President & COO Comp: $1.01MDr. Robert Janssen M.D. (Age 70)Chief Medical Officer and Senior VP of Clinical Development, Medical & Regulatory Affairs Comp: $861.52kMs. Kelly MacDonald (Age 40)Senior VP & CFO (Leave of Absence) Comp: $788.55kMr. Justin BurgessChief Accounting Officer & ControllerMr. Jeff P. Coon (Age 61)Senior VP & Chief Human Resources Officer Mr. Paul CoxVP of Investor Relations & Corporate CommunicationsMr. John L. Slebir (Age 58)Senior VP & General Counsel Mr. Donn CasaleSenior VP & Chief Commercial OfficerDr. Dong YuSenior Vice President of Vaccine ResearchMore ExecutivesKey CompetitorsProthenaNASDAQ:PRTAG1 TherapeuticsNASDAQ:GTHXUroGen PharmaNASDAQ:URGNPuma BiotechnologyNASDAQ:PBYIMarinus PharmaceuticalsNASDAQ:MRNSView All CompetitorsInsiders & InstitutionsPoint72 Asset Management L.P.Sold 90,000 shares on 8/19/2024Ownership: 0.000%Algert Global LLCBought 12,496 shares on 8/16/2024Ownership: 0.010%Millennium Management LLCBought 1,568,553 shares on 8/15/2024Ownership: 1.198%The Manufacturers Life Insurance Company Bought 4,069 shares on 8/15/2024Ownership: 0.052%ProShare Advisors LLCSold 7,214 shares on 8/14/2024Ownership: 0.021%View All Insider TransactionsView All Institutional Transactions DVAX Stock Analysis - Frequently Asked Questions How have DVAX shares performed this year? Dynavax Technologies' stock was trading at $13.98 on January 1st, 2024. Since then, DVAX shares have decreased by 18.7% and is now trading at $11.36. View the best growth stocks for 2024 here. How were Dynavax Technologies' earnings last quarter? Dynavax Technologies Co. (NASDAQ:DVAX) posted its earnings results on Tuesday, August, 6th. The biopharmaceutical company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.02. The biopharmaceutical company earned $73.80 million during the quarter, compared to analysts' expectations of $76.92 million. Dynavax Technologies had a trailing twelve-month return on equity of 1.52% and a net margin of 3.91%. What is Eddie Gray's approval rating as Dynavax Technologies' CEO? 13 employees have rated Dynavax Technologies Chief Executive Officer Eddie Gray on Glassdoor.com. Eddie Gray has an approval rating of 59% among the company's employees. This puts Eddie Gray in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 61.0% of employees surveyed would recommend working at Dynavax Technologies to a friend. Who are Dynavax Technologies' major shareholders? Dynavax Technologies' top institutional shareholders include Federated Hermes Inc. (5.46%), Chicago Capital LLC (4.28%), Dimensional Fund Advisors LP (3.00%) and Renaissance Technologies LLC (1.89%). Insiders that own company stock include Andrew A F Hack, Ryan Spencer, Robert Janssen, Francis Cano, David F Novack and Justin Burgess. View institutional ownership trends. How do I buy shares of Dynavax Technologies? Shares of DVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Dynavax Technologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dynavax Technologies investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (bmrn), (MDVN) (MDVN), Incyte (incy), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and Matinas BioPharma (MTNB). This page (NASDAQ:DVAX) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredMillionaire Investor Warns: “Brace for Apple Collapse”Apple stock has quadrupled over the past five years. But now even Warren Buffett is pulling the plug. The O...Stansberry Research | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dynavax Technologies Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dynavax Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
